Loading patent…
AssigneeHudson Institute of Medical Research
InventorsAndrew N. Stephens, Adam Rainczuk, Sung-Woog Kang
Estimating the term…
The present invention relates to C-X-C motif chemokine ligand 10 (CXCL10) binding proteins and uses thereof in methods of detecting and/or diagnosing a condition in a subject, comprising determining a level of CXCL10 in the subject. Specific antibodies that bind to total CXCL10 (full-length, N-terminally truncated and citrullinated) and antibodies that bind active CXCL10 (full-length) were used to measure the level of total and active CXCL10 in samples from ovarian cancer patients. The calculated ratio of active to total CXCL10 was lower in patients with malignant condition when compared to patients with benign tumours or healthy individuals and is the basis of method of diagnosis of malignant conditions, monitoring tumour burden and disease progression.
A C-X-C motif chemokine ligand 10 (CXCL10) binding protein, wherein the binding protein binds to full-length human CXCL10, N-terminally truncated CXCL10 and citrullinated CXCL10.
A C-X-C motif chemokine ligand 10 (CXCL10) binding protein, wherein the binding protein binds to full-length human CXCL10 with a KD of 50 nM or less, but does not bind N-terminally truncated CXCL10 and citrullinated CXCL10.
A method of detecting and/or diagnosing a malignant condition in a subject, the method comprising:
A method of monitoring tumour burden in a subject suffering from a malignant condition, the method comprising determining a CXCL10 ratio of active CXLC10 to total CXCL10 in the subject at one or more time points.
A method of monitoring progression of a malignant condition in a subject, the method comprising determining a CXCL10 ratio of active CXLC10 to total CXCL10 in the subject at one or more time points.
A method of determining tumour regression in a subject suffering from a malignant condition, the method comprising determining a CXCL10 ratio of active CXLC10 to total CXCL10 in the subject at one or more time points.
Dependencies are inferred from the claim text.